These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2006-001358-29||A Phase 2 Study of ARQ 501 in Combination with Gemcitabine in Adult Patients with Treatment Naive, Unresectable Pancreatic Adenocarcinoma||2008-08-15||due-trials|
|Not reported||2006-001942-15||A Phase 2 Study of ARQ 501 in Patients with Locally Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||2008-05-05||due-trials|
|Completed, but no date, and reported results Terminated||2007-002727-32||A Randomized Phase 2 Study of ARQ 197 versus Gemcitabine in Treatment-naïve Patients with Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma||bad-data|
|Not reported Terminated||2007-004622-25||A Randomized Phase 2 Study of ARQ 197 versus Investigator’s Choice of Second-Line Chemotherapy in Patients with Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Fo...||2008-11-07||due-trials|
|Reported results||2007-004634-17||A Randomized Phase 2 Study of Erlotinib plus ARQ 197 versus Erlotinib plus Placebo in Previously Treated Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer||2011-05-19||due-trials|
|Reported results||2008-007155-27||A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients with Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy||2012-04-18||due-trials|
|Reported results||2009-011669-10||A Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Associated Tumors||2010-12-17||due-trials|
|Ongoing||2010-020151-31||An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols||not-yet-due|
|Exempt||2015-001443-36||A Phase 1/2 Study of ARQ 087 in Adult Subjects with Advanced Solid Tumors with FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma with FGFR2||not-yet-due|
|Exempt||2016-000558-37||A Phase 1/2 Study of ARQ 092 in Patients with Overgrowth Diseases and Vascular Anomalies with Genetic Alterations of the PI3K/AKT Pathway||not-yet-due|
|Ongoing||2016-004448-12||A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions or FGFR2 gene mutations or amplifications||not-yet-due|